share_log

MindMed: Financial And Business Results For Q2 2022, Management And Pipeline Changes

Benzinga Real-time News ·  Aug 12, 2022 17:34

MindMed (NASDAQ:MNMD),which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offering a solution, reported its earnings for the quarter ended June 30, 2022. And the next day, it announced theappointment of two independent directorsto its board.

First, aquick financial report:

  • Total cash balanceof $105.7 million, expected to be sufficient for the operating requirements beyond key development milestones until 2024.

  • Net cash usedin operating activities was $28.0 million within six months, compared to $21.2 million for the same period in 2021.

  • R&D expenses were $9.3 million within three months, compared to...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment